2024-11-12 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance Overview:**

Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutrition products.

**Performance vs. S&P 500 (VOO):**

| Year       | CAGR | MDD  | Alpha | Beta | Market Cap (B) | Cumulative Return | S&P 500 Cumulative Return | Difference | Relative Divergence |
|------------|------|------|-------|------|---------------|-------------------|-----------------------------|-------------|--------------------|
| 2015-2017  | 27.1% | 24.2% | -3.1% | 1.1 | 98.99        |                  |                             |             |                    |
| 2016-2018  | 68.5% | 14.7% | 43.8% | 1.1 | 125.45       |                  |                             |             |                    |
| 2017-2019  | 122.4% | 11.7% | 79.3% | 1.0 | 150.66       |                  |                             |             |                    |
| 2018-2020  | 86.2% | 31.1% | 47.1% | 0.9 | 189.91       |                  |                             |             |                    |
| 2019-2021  | 102.5% | 31.1% | 12.7% | 0.8 | 244.11       |                  |                             |             |                    |
| 2020-2022  | 26.3% | 31.2% | 8.5% | 0.8 | 190.43       |                  |                             |             |                    |
| 2021-2023  | 0.9% | 32.7% | -28.0% | 0.7 | 190.91       | 108.24%          | 142.82%                       | -34.58%    | 9.16%                |
| 2022-2024  | -16.1% | 31.6% | -41.4% | 0.7 | 199.98       |                  |                             |             |                    |

**Analysis:**

- ABT's cumulative return over the past year (2022-2023) is 108.24%, while the S&P 500 (VOO) returned 142.82%. This results in a difference of -34.58% or a relative divergence of 9.16%. 
- This means ABT has underperformed compared to the S&P 500 over the past year but is still within the top 9.16% of its historical performance range.
- Alpha values indicate ABT's ability to outperform the market, which has fluctuated over the years, showing both positive and negative results.

**2. Recent Price Movements:**

- Closing Price: 116.59
- Last Market: 116.87
- 5-day Moving Average: 116.81
- 20-day Moving Average: 116.36
- 60-day Moving Average: 114.79

**Analysis:**

- ABT's current price is slightly above its 5-day and 20-day moving averages, suggesting a short-term bullish sentiment.
- The price is well above the 60-day moving average, indicating a longer-term upward trend.

**3. Technical Indicators:**

- **RSI:** 48.86
- **PPO:** -0.02
- **Delta_Previous_Relative_Divergence (20 days):** -5.18 (-) - Short-term downward trend.
- **Expected Return:** 0.0%

**Analysis:**

- The RSI is close to 50, indicating neutral sentiment.
- The PPO is negative, suggesting potential bearish momentum.
- The recent relative divergence shows a short-term downward trend.
- The expected return of 0% suggests no significant outperformance potential compared to the S&P 500 over the long term (2+ years).

**4. Recent Earnings and Outlook:**

| Date        | EPS | Revenue |
|-------------|-----|---------|
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2024-10-31 | 0.82 | 10.14 B$ |

**Analysis:**

- ABT's most recent earnings (2024-10-31) exceeded expectations, with EPS reaching $0.94 and revenue at $10.63 billion. 
- Revenue has remained stable, consistently above $10 billion, demonstrating steady performance. 
-  ABT's earnings have been relatively consistent over the last few quarters, suggesting a stable business model and predictable growth. 

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2024-09-30 | $10.63B | 55.83%       |
| 2024-06-30 | $10.38B | 55.64%       |
| 2024-03-31 | $9.96B | 55.21%       |
| 2023-12-31 | $10.24B | 55.51%       |
| 2023-09-30 | $10.14B | 54.60%       |

**Capital and Profitability:**

| Quarter      | Equity | ROE |
|--------------|--------|-----|
| 2024-09-30 | $39.80B | 4.14% |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |

**Analysis:**

- ABT demonstrates consistent profitability with high profit margins around 55%.
- The company's return on equity (ROE) has been fluctuating but remains above 3%, indicating effective utilization of shareholders' equity. 
- Stable revenue and consistent profitability suggest a strong and reliable business model.

**6. News and Recent Issues:**

**Latest Earnings News:**

- *Shacknows* published an earnings report on **November 1, 2023** for ABT, showing a beat on both EPS and revenue estimates. The report highlights ABT's strong performance in the medical device segment, specifically in its diabetes care business.

**Recent Market Outlook:**

- According to *Finbold*, ABT's stock has been performing well in recent months, driven by its strong earnings performance and positive market sentiment. 

**Analyst Opinions and Performance Highlights:**

- Most analysts have a **"Buy" or "Hold" rating** on ABT. They generally cite the company's stable growth, diversified business model, and dividend payouts as reasons for their positive outlook. 

**7. Overall Analysis:**

- ABT is a well-established healthcare company with a robust track record of stable growth and consistent profitability. 
- Its strong earnings performance and diversified business model have contributed to positive market sentiment and analyst confidence. 
- While the recent performance has slightly lagged behind the S&P 500, ABT remains a solid investment option, particularly for investors seeking a stable and reliable dividend payer. 

**Disclaimer:** 
This is an automated analysis and should not be considered financial advice. It is essential to conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
